Silvia Damian

Also affiliated with Fondazione IRCCS Istituto Nazionale dei Tumori

Biochemistry, Genetics and Molecular BiologyMedicineNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial”.

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Nature Medicine(2024)10.1038/s41591-024-02934-7

N/A

0.637DataRank · unranked

69 citations

Silvia Damian, Muhammad Furqan, Jesús García-Donás, Hiroo Imai, Antoîne Italiano +10 more

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2022.09.229

N/A

0DataRank · unranked

3 citations

Silvia Damian, Matteo Duca, S. Della Valle, Filippo de Braud, Leonardo Provenzano